The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition
Open accessAbstract
The ubiquitin-proteasome pathway degrades ubiquitinated proteins to remove damaged or misfolded protein and thus plays an important role in the maintenance of many important cellular processes. Because the pathway is also crucial for tumor cell growth and survival, proteasome inhibition by specific inhibitors exhibits potent antitumor effects in many cancer cells. xCT, a subunit of the cystine antiporter system xc (-), plays an important role in cellular cysteine and glutathione homeostasis. Several recent reports have revealed that xCT is involved in cancer cell survival; however, it was unknown whether xCT affects the cytotoxic effects of proteasome inhibitors. In this study, we found that two stress-inducible transcription factors, Nrf2 and ATF4, were upregulated by proteasome inhibition and cooperatively enhance human xCT gene expression upon proteasome inhibition. In addition, we demonstrated that the knockdown of xCT by small interfering RNA (siRNA) or pharmacological inhibition of xCT by sulfasalazine (SASP) or (S)-4-carboxyphenylglycine (CPG) significantly increased the sensitivity of T24 cells to proteasome inhibition. These results suggest that the simultaneous inhibition of both the proteasome and xCT could have therapeutic benefits in the treatment of bladder tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“Nrf2 also activates cancer cell growth through metabolic reprogramming (58).”
BackgroundIshimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192 · cited 1×
“In addition, a CD44 variant promotes tumor growth by stabilizing the xCT protein (29).”
BackgroundGout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399
Cited by
Ferroptosis: molecular mechanisms and health implications
Tang, D., Chen, X., Kang, R., & Kroemer, G. (2021) · Cell Research · doi:10.1038/s41422-020-00441-1 · Cited by 4,256
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,487
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018) · Cancer Communications · doi:10.1186/s40880-018-0288-x · Cited by 915
ATF3 promotes erastin-induced ferroptosis by suppressing system Xc–
Wang, L., Liu, Y., Du, T., Yang, H., Lei, L., Guo, M., Ding, H.-F., Zhang, J., Wang, H., Chen, X., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0380-z · Cited by 809
NRF2 regulates serine biosynthesis in non–small cell lung cancer
DeNicola, G. M., Chen, P.-H., Mullarky, E., Sudderth, J. A., Hu, Z., Wu, D., Tang, H., Xie, Y., Asara, J. M., Huffman, K. E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3421 · Cited by 746
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
Fan, Z., Wirth, A.-K., Chen, D., Wruck, C. J., Rauh, M., Buchfelder, M., & Savaskan, N. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.65 · Cited by 692
Ferroptosis in cancer and cancer immunotherapy
Zhao, L., Zhou, X., Xie, F., Zhang, L., Yan, H., Huang, J., Zhang, C., Zhou, F., Chen, J., & Zhang, L. (2022) · Cancer Communications · doi:10.1002/cac2.12250 · Cited by 684
Characterization of ferroptosis in murine models of hemochromatosis
Wang, H., An, P., Xie, E., Wu, Q., Fang, X., Gao, H., Zhang, Z., Li, Y., Wang, X., Zhang, J., et al. (2017) · Hepatology · doi:10.1002/hep.29117 · Cited by 660
Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells
Wortel, I. M. N., van der Meer, L. T., Kilberg, M. S., & van Leeuwen, F. N. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.07.003 · Cited by 609
Regulation of Nrf2 by Mitochondrial Reactive Oxygen Species in Physiology and Pathology
Kasai, S., Shimizu, S., Tatara, Y., Mimura, J., & Itoh, K. (2020) · Biomolecules · doi:10.3390/biom10020320 · Cited by 566
Self-citationThe Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11
Liu, T., Jiang, L., Tavana, O., & Gu, W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3037 · Cited by 490
Self-citationFerroptosis and Its Role in Diverse Brain Diseases
Weiland, A., Wang, Y., Wu, W., Lan, X., Han, X., Li, Q., & Wang, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1403-3 · Cited by 467
The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy
Zhao, Y., Li, Y., Zhang, R., Wang, F., Wang, T., & Jiao, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s254995 · Cited by 458
Hu, K., Li, K., Lv, J., Feng, J., Chen, J., Wu, H., Cheng, F., Jiang, W., Wang, J., Pei, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci124049 · Cited by 404
ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis
He, F., Zhang, P., Liu, J., Wang, R., Kaufman, R. J., Yaden, B. C., & Karin, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.016 · Cited by 390
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J.-L., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 373
xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression
Ji, X., Qian, J., Rahman, S. M. J., Siska, P. J., Zou, Y., Harris, B. K., Hoeksema, M. D., Trenary, I. A., Heidi, C., Eisenberg, R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0307-z · Cited by 350
xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling
Liu, J., Xia, X., & Huang, P. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.021 · Cited by 347
NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression
Chen, D., Tavana, O., Chu, B., Erber, L., Chen, Y., Baer, R., & Gu, W. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.009 · Cited by 317
Lim, J. K. M., Delaidelli, A., Minaker, S. W., Zhang, H.-F., Colovic, M., Yang, H., Negri, G. L., von Karstedt, S., Lockwood, W. W., Schaffer, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821323116 · Cited by 308
Koppula, P., Zhang, Y., Shi, J., Li, W., & Gan, B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.798405 · Cited by 304
CHEN, L., LI, X., LIU, L., YU, B., XUE, Y., & LIU, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.3712 · Cited by 279
RetractedThe Non-Essential Amino Acid Cysteine Becomes Essential for Tumor Proliferation and Survival
Combs, J. A., & DeNicola, G. M. (2019) · Cancers · doi:10.3390/cancers11050678 · Cited by 272
Habib, E., Linher-Melville, K., Lin, H.-X., & Singh, G. (2015) · Redox Biology · doi:10.1016/j.redox.2015.03.003 · Cited by 271
System Xc−: a key regulatory target of ferroptosis in cancer
Liu, M.-R., Zhu, W.-T., & Pei, D.-S. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01070-0 · Cited by 254
Gwinn, D. M., Lee, A. G., Briones-Martin-del-Campo, M., Conn, C. S., Simpson, D. R., Scott, A. I., Le, A., Cowan, T. M., Ruggero, D., & Sweet-Cordero, E. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.003 · Cited by 230
Chaudhary, N., Choudhary, B. S., Shah, S. G., Khapare, N., Dwivedi, N., Gaikwad, A., Joshi, N., Raichanna, J., Basu, S., Gurjar, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33711 · Cited by 185
Reprogramming of serine, glycine and one-carbon metabolism in cancer
Li, A. M., & Ye, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165841 · Cited by 127
Haddad, M., Hervé, V., Ben Khedher, M. R., Rabanel, J.-M., & Ramassamy, C. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8129 · Cited by 68
Metabolic features of cancer cells in NRF2 addiction status
Okazaki, K., Papagiannakopoulos, T., & Motohashi, H. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00659-8 · Cited by 57
Metadata
- Authors
- Ye, P., Mimura, J., Okada, T., Sato, H., Liu, T., Maruyama, A., Ohyama, C., & Itoh, K.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2014-09-01
- Volume
- 34
- Issue
- 18
- Pages
- 3421-3434
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2165129832
- Cited by
- 208
- References
- 7
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.